Alnylam Pharmaceuticals Inc (ALNY NASDAQ) stock market data APIs
$328.8857
0.02(0%)
as of February 6, 2026
Try our APIs with
free plan!
Alnylam Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Prev. Close
328.8857
Open
328.9106
High
336.7368
Low
325.4639
52 wk Range
205.87-495.55
Market Cap
43 354 M
P/E Ratio
1093.8666
Shares Outstanding
132 M
Revenue
3 210 M
EPS
0
Beta
0.351
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alnylam Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alnylam Pharmaceuticals Inc data using free add-ons & libraries
Get Alnylam Pharmaceuticals Inc Fundamental Data
Alnylam Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 3 210 M
- EBITDA: 321 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-12
- EPS/Forecast: 1.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alnylam Pharmaceuticals Inc News
New
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't?
Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2026 $170.00 Call had some of the high...
3 Stocks Estimated To Be Trading At Discounts Of Up To 49.2%
As the United States stock market begins February on a high note, with major indices like the Dow Jones and S&P 500 showing significant gains, investors are closely monitoring opportunities amidst flu...
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Alnylam Pharmaceuticals (ALNY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...
Discounted Value Stocks With Estimated Upside In February 2026
As February 2026 begins, the U.S. stock market is experiencing a robust start with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains, signaling positive investo...
Get Alnylam Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
